Anaphylaxis

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Retrieved on: 
水曜日, 5月 29, 2024
Oncology, Health, Clinical Trials, General Health, Radiology, Biotechnology, PET, Blood pressure, Diarrhea, Doctor of Philosophy, Recurrence, Exhibit, Risk, University, SNMMI, FDA, Lymph, Serum, Radiation, Level, MD, ADT, Prostate cancer, PSA, Cancer, Dysgeusia, MedStar Georgetown University Hospital, F 18, Anaphylaxis, Antiandrogen, Medical imaging

Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.

Key Points: 
  • Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.
  • The Company is hosting a Satellite Symposium, “Let’s Talk about POSLUMA®,” which will discuss the most recent innovations in PSMA-PET imaging for prostate cancer.
  • Blue Earth Diagnostics also has a Medical Affairs information booth at SNMMI, where attendees can learn about the Company’s clinical research.
  • A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence.

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference

Retrieved on: 
火曜日, 5月 28, 2024
Patient, American Academy, PD, Asthma, Immunology, FDA, Therapy, Adrenaline, Allergy, Conference, EAC, Pharmacokinetics, Anaphylaxis, American College, Pharmaceutical industry

WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two encore poster presentations highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies for Anaphylm™ (epinephrine) sublingual film will be presented at the Eastern Allergy Conference (EAC).

Key Points: 
  • WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two encore poster presentations highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies for Anaphylm™ (epinephrine) sublingual film will be presented at the Eastern Allergy Conference (EAC).
  • Taking place from May 30 through June 2, 2024, in Palm Beach, Florida, EAC features the most current information from the field's top experts on Allergy, Asthma and Immunology.
  • Anaphylm is the Company’s first and only orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
  • “Anaphylm has the potential to transform the treatment of severe allergic reactions, including anaphylaxis.

Stallergenes Greer Foundation Announces Winners of 2023 Science Awards for Allergy

Retrieved on: 
月曜日, 5月 27, 2024
Health, Hospitals, General Health, Research, Pharmaceutical, Science, The central science, University, Disease, Asthma, Teaching hospital, Harvard University, Medicine, Peanut, Allergy, Peanut allergy, Microbiology, MD, University Medical Center, Environmental Health (journal), Research institute, Anaphylaxis, University of Queensland, Murdoch Children's Research Institute, University of Cape Town, Knowledge Organization (journal), File association, Associate professor, Pollen, Public, Epidemiology, Vorstand, Internal medicine, Senior lecturer, Doctor of Philosophy, Prevalence, Food allergy, Stallergenes Greer, History, Public health, Pharmaceutical industry

The Stallergenes Greer Foundation, dedicated to fostering innovation and precision medicine in the field of allergy, is delighted to announce the recipients of the 2023 edition of its prestigious Science Awards for Allergy.

Key Points: 
  • The Stallergenes Greer Foundation, dedicated to fostering innovation and precision medicine in the field of allergy, is delighted to announce the recipients of the 2023 edition of its prestigious Science Awards for Allergy.
  • These awards recognise outstanding contributions to allergy research and environmental health initiatives and allocate up to €150,000 to support these efforts.
  • Michele Antonelli, CEO of Stallergenes Greer and Chairman of the Stallergenes Greer Foundation, expresses his congratulations to the award recipients.
  • “These researchers exemplify the spirit of innovation and dedication that the Stallergenes Greer Foundation seeks to promote.

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

Retrieved on: 
水曜日, 5月 22, 2024
ATP, ACL, Risk, Molina Healthcare, Ageing, Agent handling, Adverse event, CVD, Esperion Therapeutics, Back pain, Angioedema, Cholesterol, Gout, Kidney, Constipation, Treatment, Civil service commission, European Commission, Fetus, Anaphylaxis, Hypersensitivity, Moyamoya disease, Bempedoic acid, Urinary tract infection, Anemia, Hypercholesterolemia, Upper respiratory tract infection, Safety, Ezetimibe, CLEAR, Incidence, Bronchitis, Excipient, Diet, Gallstone, Rash, Patient, Cardiovascular disease, Diarrhea, Abdominal pain, Uric acid, Spasm, University, University of Milan, Therapy, Arthralgia, Sinusitis, Pregnancy, European, Stroke, Health, Common, Death, FDC, Fatigue, Myocardial infarction, Tablet, Rupture, Pain, CHMP, Dietary supplement

ANN ARBOR, Mich. and MUNICH, Germany, May 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics, Inc. jointly announced today that the European Commission (EC) has approved the label update of both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination (FDC)), as treatments for hypercholesterolemia (high levels of cholesterol) and to reduce the risk of adverse cardiovascular events. The EC’s decisions to update the labels of bempedoic acid and bempedoic acid / ezetimibe FDC are based on the positive CLEAR Outcomes trial results and makes them the first and only LDL-C lowering treatments indicated for primary and secondary prevention of cardiovascular events.

Key Points: 
  • Bempedoic acid is a first-in-class oral treatment which lowers cholesterol, and which can be combined with other treatments to help lower cholesterol even further.
  • Bempedoic acid provided additional cholesterol lowering of up to 28% on top of statin therapy, compared to placebo.
  • “Today's announcement marks a pivotal moment in our ongoing efforts to reduce cardiovascular risk.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Safer Skies Ahead: Congress Approves Legislation Requiring Updates to Airline Emergency Medical Kits

Retrieved on: 
水曜日, 5月 15, 2024
Legislation, Asthma, Friends, Education, Calendar, Aerospace Medical Association, Adrenaline, Allergy, Congress, Food, Airlines for America, Senate, House, EMK, Anaphylaxis, AAFA, Federal Aviation Administration, Language, Pharmaceutical industry

The U.S. House and Senate passed legislation reauthorizing the Federal Aviation Administration that includes a requirement that emergency medical kits (EMKs) on airplanes be equipped to treat anaphylaxis, a serious allergic reaction that progresses rapidly.

Key Points: 
  • The U.S. House and Senate passed legislation reauthorizing the Federal Aviation Administration that includes a requirement that emergency medical kits (EMKs) on airplanes be equipped to treat anaphylaxis, a serious allergic reaction that progresses rapidly.
  • “This legislation represents a tremendous step forward for people with food allergies traveling on commercial airplanes,” said Kenneth Mendez, president and CEO of AAFA.
  • Additionally, the reauthorization calls for a review of the contents of these medical kits at least every five years.
  • AAFA has consistently called on the FAA and Congress to act to ensure easy-to-use epinephrine is available on commercial airplanes.

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
CSL Limited, FDA, Investment, NDA, Research, MAA, CHMP, ASX, Trial of the century, ARS, PDUFA, European Medicines Agency, Patient, Adrenaline, Anaphylaxis, CSL, EMA, Caregiver, Committee, Allergy, Upper respiratory tract infection, CRL, Clinical trial, SAN, Journal, G&A

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the first quarter of 2024.

Key Points: 
  • Assuming approval on or before the anticipated PDUFA date, ARS Pharma anticipates launching neffy in the U.S. in the second half of 2024.
  • Following local regulatory approval of neffy, ARS Pharma will be responsible for supplying finished product to CSL Seqirus at a transfer price paid to ARS Pharma.
  • G&A expenses decreased from 2023 to 2024 primarily due to a pause in pre-commercial launch activities related to neffy.
  • Net Loss: Net loss was $10.3 million for the quarter ended March 31, 2024, compared to $15.0 million for the quarter ended March 31, 2023.

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
火曜日, 5月 7, 2024
Angioedema, FDA, Mouth, NDA, Food, Swelling, Skin, Research, Attention deficit hyperactivity disorder, Insurance, Trial of the century, ADHD, Lennox–Gastaut syndrome, Dermatology, Seizure, Prescription, Public expenditure, Riluzole, Vomiting, Patent, Patient, Adrenaline, Common stock, Anaphylaxis, Epilepsy, Diazepam, PD, Therapy, Serdexmethylphenidate/dexmethylphenidate, Type, Pharmaceutical industry

“We continue to successfully execute on our growth strategy as demonstrated by our first quarter results,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “We continue to successfully execute on our growth strategy as demonstrated by our first quarter results,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • Total revenues increased to $12.1 million in the first quarter 2024 from $11.1 million in the first quarter 2023.
  • Research and development expenses increased to $5.9 million in the first quarter 2024 from $3.5 million in the first quarter 2023.
  • Non-GAAP adjusted EBITDA loss was $7.2 million in the first quarter 2024, compared to non-GAAP adjusted EBITDA loss of $3.9 million in the first quarter 2023.

AAFA Co-Hosts Congressional Briefing Highlighting 25th Year of National Asthma Control Program

Retrieved on: 
火曜日, 5月 7, 2024
Mortality, Public, Climate change, United, Allergist, Risk, CDC, Health, Pollen, Congress, NACP, Dingell, AAFA, Public policy, Food, Air pollution, Legislation, World Asthma Day, Anaphylaxis, Alaska Natives, Allergy, Atopic dermatitis, Quality of life, Polyp (medicine), Eosinophilic esophagitis, COVID-19, Calendar, RSV, Pharmaceutical industry

Washington, DC, May 07, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating the 25th year of the CDC’s National Asthma Control Program (NACP) on World Asthma Day (May 7) by co-hosting a Congressional briefing highlighting the program’s impact and calling attention to the need to expand the program to all of the United States.

Key Points: 
  • Washington, DC, May 07, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating the 25th year of the CDC’s National Asthma Control Program (NACP) on World Asthma Day (May 7) by co-hosting a Congressional briefing highlighting the program’s impact and calling attention to the need to expand the program to all of the United States.
  • “The NACP provides resources for asthma education that help empower people with asthma,” said Kenneth Mendez, president and CEO of AAFA.
  • And for every $1 spent, the NACP saves $71 in total economic costs related to asthma.
  • On behalf of the 27 million people in the US with asthma, we’re grateful for the positive impact NACP has made over the past 25 years.

Multi Radiance Medical Renews Long-Term Global Sponsorship With ISELP

Retrieved on: 
木曜日, 5月 9, 2024
Veterinary, Other Manufacturing, Medical Devices, Pets, Health Technology, Manufacturing, Biotechnology, General Health, Consumer, Health, Relaxation, FDA, International Society, Veterinarian, Partnership, Light, Limp, DVM, Laser, Anaphylaxis, FEI, Horse, Medical imaging

Multi Radiance Medical , manufacturer and world-leader in laser and light-based technology, is proud to renew its long-term Global Sponsor partnership with the International Society of Equine Locomotor Pathology (ISELP) .

Key Points: 
  • Multi Radiance Medical , manufacturer and world-leader in laser and light-based technology, is proud to renew its long-term Global Sponsor partnership with the International Society of Equine Locomotor Pathology (ISELP) .
  • “As a leader in equine laser therapy, it is only fitting that we continue to partner with the highest level of equine veterinarians, and ISELP represents just that,” says Max Kanarsky, President and CEO of Multi Radiance Medical.
  • Kent Allen, DVM, ISELP board member and chair of the USEF Drugs and Medications Committee and Veterinarian Committee, says, "Science-based adjunctive treatments provide alternatives that help reduce drug-related side effects, making Multi Radiance an ideal partner."
  • I’m seeing reduced healing times, and improvements in healing in some cases unresponsive to a conventional approach.”
    To learn more about Multi Radiance and WellVu visit: https://info.multiradiance.com/vet/mrv_iselp

Allergy & Asthma Day Capitol Hill on May 8: Advancing Health Equity for All

Retrieved on: 
水曜日, 5月 1, 2024
Education, Congress, Law, Bangladesh Technical Education Board, Health equity, EPA, Investment, HELP, Risk, NIH, CDC, Allergy, Health, Collection, Research, Asthma, Native, Patient, Adrenaline, Legislation, Anaphylaxis, Clinical trial, Pharmaceutical industry

On May 8, Allergy & Asthma Network is hosting its 27th annual Allergy & Asthma Day Capitol Hill (AADCH) in Washington, DC to advocate for healthcare policies and legislation that leave no one behind – regardless of race, ethnicity, education, income level or where they live.

Key Points: 
  • On May 8, Allergy & Asthma Network is hosting its 27th annual Allergy & Asthma Day Capitol Hill (AADCH) in Washington, DC to advocate for healthcare policies and legislation that leave no one behind – regardless of race, ethnicity, education, income level or where they live.
  • The theme this year is "Breaking Barriers: Advancing Health Equity for All."
  • "Health disparities create barriers to accessing care and achieving optimal health," says Lynda Mitchell, CEO of Allergy & Asthma Network.
  • "We are excited to head back to Capitol Hill to advocate for legislation that is patient-first and reinforces health equity," says Charmayne Anderson, Director of Advocacy at Allergy & Asthma Network.